Table 4. . Frequency of ITGA4 hypermethylation of the significant CpG sites among patients and controls.

ITGA4 gene methylation % of CpG sites	CLL patients, number (%)	Controls, number (%)	Odds ratio (95% CI)	Chi-square significance (p-value)
CpG site-1 >12.5 %	80 (98.7)	3 (4)	23.6 (3.47–161.1)	<0.001†
CpG site-2 >2.5 %	46 (56.8)	16 (21.3)	1.448 (1.131–1.853)	0.004‡
CpG site-3 >3.5 %	42 (51.8)	16 (21.3)	1.384 (1.093–1.751)	0.009‡

^†p < 0.05 is considered significant;

^‡p < 0.01 is considered highly significant.

CLL: Chronic lymphocytic leukemia.